Post-Covid, Insilico has also set up a site in Shanghai.Īlex is frustrated by the growing resistance to international co-operation in pharmaceutical research. Alex reports that Hong Kong still has great IP protection, deep financial expertise, world-class scientific resources, and is a beautiful place to live. It is also easier in some ways to do clinical studies in China, although the company has to duplicate them in other territories which may not accept foreign data. Using Contract Research Organisations (CROs) in China enabled Insilico to do research without having its own wetlab. Alex was born in Latvia, he studied in Canada, he started his career in the US, and he established Insilico in Hong Kong. Insilico is very much a global organisation. The problem with this is that either somebody else owns the intellectual property (IP) in these drugs, and you have to license them, or they are already generic, which means there is little prospect of earning a commercial return on the development costs. One way to shorten the timeline of drug development is to re-purpose existing drugs for new diseases, since they are already known to be safe for human use.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |